Lower GCS is Related to Poor Outcome among Acute Stroke Patients with  COVID-19 in A Tertiary Referral Hospital in Indonesia

Kembuan, Mieke A. H. N.; Mawuntu, Arthur H.P.; Yohanna, Yohanna; Feliana, Feliana; Tumboimbela, Melke J.

doi:10.18585/inabj.v13i4.1700

Cited by 2 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding the chest condition, oxygen saturation decreased in the blood, which led to anorexia and deteriorated consciousness and GCS. In patients with preexisting spontaneous intracerebral hemorrhage and COVID-19 infection, a lower GCS can be considered a predictor of poor outcomes [47,48].…”

Section: Discussionmentioning

confidence: 99%

The Outcomes of COVID-19 Patients with Spontaneous Intracerebral Hemorrhage Comorbidity and the Efficacy of Enoxaparin in Decreasing the Mortality Rate in Them: Single Egyptian Center Report

Shaban

Elgendy

Fahmy

et al. 2022

JPM

View full text Add to dashboard Cite

Patients with neurological comorbidities are more likely to develop severe COVID-19. We aimed to detect the outcomes of COVID-19 patients with spontaneous intracerebral hemorrhage comorbidity and the role of enoxaparin in decreasing the mortality rate in these cases, even though enoxaparin is a potential cause of intracerebral hemorrhage. The patients were checked on to detect surveillance outcomes, the relationship between mortality and patient characteristics, and the relationship between enoxaparin and study outcomes. Chest condition and GCS improved in 67.9% of participants. Hematoma course increased in 49.1%. Midline-shift, brain-edema, and COVID symptoms improved in 67.9%. There was a non-significant difference in mortality regarding age and gender. There was a significant difference in mortality regarding treatment with enoxaparin; 75% of the patients who did not receive enoxaparin died. 92.6% of the patients who showed decreases in hematoma course were administered enoxaparin. 76.9% of the patients who showed increases in hematoma-course were administered enoxaparin. Most of the patients who were admitted to the neurosurgical unit with spontaneous intracerebral hemorrhage acquired the COVID-19 infection. Most of the cases included in this study did not progress to severe cases. The dying patients showed deterioration in both neurological and COVID-19 symptoms. The anticoagulant properties of enoxaparin given earlier before and throughout the infection can considerably reduce mortality in COVID-19 individuals with spontaneous intracerebral hemorrhage. It is recommended to use enoxaparin for cases with spontaneous intracerebral hemorrhage and COVID-19 regardless of hematoma size because the rate of improvement was greater than the mortality rate after using enoxaparin in this study.

show abstract

Section: Discussionmentioning

confidence: 99%

The Outcomes of COVID-19 Patients with Spontaneous Intracerebral Hemorrhage Comorbidity and the Efficacy of Enoxaparin in Decreasing the Mortality Rate in Them: Single Egyptian Center Report

Shaban

Elgendy

Fahmy

et al. 2022

JPM

View full text Add to dashboard Cite

show abstract

“…In COVID-19-infected patients with ARDS and fulminant, classic serum biomarkers produced by the release of cytokines have been found, particularly elevated C-reactive protein (CRP), lactate dehydrogenase (LDH), and IL-6, lactate dehydrogenase (LDH). 2,5,19 Therefore, avoiding or reducing cytokine storm is the key to treating COVID-19-infected patients.…”

Section: Covid-19 Pathogenesismentioning

confidence: 99%

Allogeneic Mesenchymal Stem Cells and Its Conditioned Medium as a Potential Adjuvant Therapy for COVID-19

Widowati

Faried

Kusuma³

et al. 2023

Mol Cell Biomed Sci

View full text Add to dashboard Cite

Recent research has demonstrated that mesenchymal stem cells (MSCs) potentially benefit and enhance coronavirus disease (COVID-19) recovery. This benefit occurs via a mechanism that promotes viral clearance by phagocytes and macrophages. This action occurs through the innate (increase in IL-10 production and decrease in TNF-α and IL-12 production) and the adaptive immune system (decrease in IL-17 production, promote regulatory T cell proliferation and inhibit effectors T cell proliferation). MSCs are expected to act as an anti-inflammatory in the hyper-inflammatory state of COVID-19. MSCs enhance immune cell replacement that have been overwhelmed or have been lost due to cytokine storm. Although vaccines are the answer to this pandemic, MSCs can improve COVID-19 patients, especially in patients with chronic illnesses. The focus on keeping death-rates low is a great opportunity for MSCs-based therapy for severe or critically ill patients. MSCs and conditioned medium have the potential to serve as adjunctive therapy in preventing the body's overactive defense response or the so-called cytokine storm caused by COVID-19.Keywords: adjuvant therapy, COVID-19, mesenchymal stem cells, secretome

show abstract

Lower GCS is Related to Poor Outcome among Acute Stroke Patients with COVID-19 in A Tertiary Referral Hospital in Indonesia

Cited by 2 publications

References 14 publications

The Outcomes of COVID-19 Patients with Spontaneous Intracerebral Hemorrhage Comorbidity and the Efficacy of Enoxaparin in Decreasing the Mortality Rate in Them: Single Egyptian Center Report

The Outcomes of COVID-19 Patients with Spontaneous Intracerebral Hemorrhage Comorbidity and the Efficacy of Enoxaparin in Decreasing the Mortality Rate in Them: Single Egyptian Center Report

Allogeneic Mesenchymal Stem Cells and Its Conditioned Medium as a Potential Adjuvant Therapy for COVID-19

Contact Info

Product

Resources

About